DUBLIN – Veteran German antibody developer Morphosys AG swelled the ranks of European biotech firms on Nasdaq by grossing $207.8 million from an offering of 8.3 million American depositary shares, which it priced at $25.04 per share. If exercised, an overallotment option comprising 1.245 million shares would add another $37.35 million to the proceeds. Shares in the Martinsried-based firm began trading today under the ticker symbol MOR, and quickly went into positive territory, reaching $26.47 at one point and ending the day at $26.31.